1:48 What should advanced practitioners look for with CLL patients that also have lymphocytosis? JADPRO Live 2015 67 views - 10 years ago
1:54 What test should an advanced practitioner order if CLL is suspected? JADPRO Live 2015 16 views - 10 years ago
2:02 In the era of high response rates seen in immunotherapy combinations... JADPRO Live 2015 39 views - 10 years ago
1:25 What are the toxicities associated with the agents used for multiple myeloma? JADPRO Live 2015 9 views - 10 years ago
1:19 What are some monitoring parameters for toxicities to establish? JADPRO Live 2015 14 views - 10 years ago
1:34 How can I increase patient adherence to treatment regimens for multiple myeloma? JADPRO Live 2015 26 views - 10 years ago
0:58 What does an advanced practitioner need to know to create an optimal treatment regimen? JADPRO Live 2015 22 views - 10 years ago
0:56 How does Bruton's tyrosine kinase differ from other tyrosine kinases? JADPRO Live 2015 429 views - 10 years ago
2:02 The monoclonal antibodies rituximab, obinutuzumab, and ofatumumab all target CD20... JADPRO Live 2015 764 views - 10 years ago
1:29 What comorbidities should be taken into account before dosing with dinutuximab? JADPRO Live 2015 124 views - 10 years ago
1:05 What types of symptoms do patients diagnosed with a neuroendocrine tumor have? JADPRO Live 2015 67 views - 10 years ago
1:02 What is the difference between a biologic and a biosimilar? JADPRO Live 2015 98 views - 10 years ago
0:59 What should be taken into consideration about the manufacture of biosimilars? JADPRO Live 2015 9 views - 10 years ago
1:09 How will biosimilars hopefully improve patient access to treatment? JADPRO Live 2015 19 views - 10 years ago
1:56 What should advanced practitioners know about the side effect profiles of targeted treatments? JADPRO Live 2015 5 views - 10 years ago
2:02 What should pharmacists know about combining treatment agents for patients with NSCLC? JADPRO Live 2015 13 views - 10 years ago
0:52 What are the biggest challenges of managing high-risk neuroblastoma? JADPRO Live 2015 182 views - 10 years ago
2:35 What is the evidence from the PROMID and CLARINET clinical trials for use of somatostatin analogs? JADPRO Live 2015 78 views - 10 years ago
2:09 What do the NCCN guidelines recommended for diagnostic testing in patients being treated for pNET? JADPRO Live 2015 25 views - 10 years ago
1:53 Can you give us an overview of the classification system of neuroendocrine tumors? JADPRO Live 2015 25 views - 10 years ago
1:06 How does the side effect profile of immunotherapies compare with that of standard chemotherapy? JADPRO Live 2015 5 views - 10 years ago
1:05 What is the best way to combine immunotherapy with traditional cytotoxic chemotherapy? JADPRO Live 2015 19 views - 10 years ago
2:24 What are the differences in the side effect profile between the monoclonal antibody treatments? JADPRO Live 2015 284 views - 10 years ago
2:16 For patients with neuroblastoma receiving immunotherapy... JADPRO Live 2015 243 views - 10 years ago
1:33 How do immune-related adverse events differ from toxicities seen in targeted or chemotherapies? JADPRO Live 2015 97 views - 10 years ago
1:42 Do you have any practical "take-away" clinical tips for APs in the community setting? JADPRO Live 2015 13 views - 10 years ago
1:08 What elements should be included in the education of patient and families receiving dinutuximab? JADPRO Live 2015 56 views - 10 years ago
0:53 What is the importance of an interprofessional approach in the management of a patient? JADPRO Live 2015 17 views - 10 years ago
2:13 How does the combination of CTLA-4 and PD-1 agents enhance treatment outcomes for melanoma patients? JADPRO Live 2015 87 views - 10 years ago
1:51 Briefly define low-risk vs high risk patient risk stratification JADPRO Live 2015 113 views - 10 years ago
1:43 ow should biomarkers for CTLA-4 and PD-L1 be integrated in patients with melanoma? JADPRO Live 2015 28 views - 10 years ago
0:53 Why is an interprofessional approach and family centered care important? JADPRO Live 2015 8 views - 10 years ago
1:02 What are some modalities that can reduce or eliminate pain-associated suffering? JADPRO Live 2015 10 years ago
0:45 How do you decide if you're going to prescribe a biosimilar to your patients? JADPRO Live 2015 9 views - 10 years ago
1:17 ow do you identify a patient with high-risk neuroblastoma? JADPRO Live 2015 123 views - 10 years ago
1:38 What is the role of EGFR mutations in patients with NSCLC? JADPRO Live 2015 33 views - 10 years ago
2:11 What are important considerations for APs in the management of side effects in patients? JADPRO Live 2015 10 views - 10 years ago
0:43 What is T790m and describe its role in drug resistance? JADPRO Live 2015 54 views - 10 years ago
1:47 What is ALK and how does it impact the treatment of NSCLC? JADPRO Live 2015 48 views - 10 years ago
3:14 What guidance would you offer advanced practitioners caring for patients with refractory CINV? JADPRO Live 2015 6 views - 10 years ago
1:19 What adverse effects are associated with somatostatin analog treatments? JADPRO Live 2015 528 views - 10 years ago